Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

- PMLiVE

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

About 15,000 people in England are living with the inherited blood disorder

- PMLiVE

ICR researchers uncover new method for predicting bowel cancer risk in IBD patients

Approximately 500,000 people in the UK are affected by Crohn’s disease or ulcerative colitis

- PMLiVE

Keto, CAR-T and creativity: insights from ASH 2024

With a menu featuring everything from cutting-edge science to DEI and diet, ASH 2024 certainly offered congress attendees food for thought

- PMLiVE

See What’s Shaping Pharma Education in 2025: Join Our Free Webinar

From AI to VR, and everything in between—explore the cutting-edge tools revolutionizing medical training. Learn why these advancements are crucial for maintaining standards and excelling in the rapidly evolving landscape...

Impetus Digital

Optimizing Team Meetings in Remote Work – Building Company Culture Virtually

Rethink your approach to team meetings in a remote setting. Discover strategies for balancing synchronous and asynchronous communications to maximize decision-making and minimize meeting fatigue. Explore our tips for structuring...

Impetus Digital

- PMLiVE

UK access pathway launched to get new medicines to patients in ‘shortest time possible’

The ILAP offers drug developers a single platform to collaborate with the MHRA and HTA bodies

- PMLiVE

Sanofi’s Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma

An estimated 5,900 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Roche shares positive overall survival results for Itovebi in advanced breast cancer

Approximately 56,800 new cases of breast cancer are diagnosed in the UK every year

- PMLiVE

The AI tipping point in pharma marketing: balancing technology and trust

Taking a closer look at the opportunities and challenges AI offers pharma marketers

Biogen Idec building

Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA

The neuromuscular disease affects approximately one in every 10,000 babies worldwide

- PMLiVE

Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

The progressive condition affects approximately 40% of type 2 diabetes patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links